Founded on the growing insight into the complex cancer-immune system interactions, adjuvant immunotherapies are rapidly emerging and being adapted for the treatment of various human malignancies. Immune checkpoint inhibitors, for example, have already shown clinical success. Nevertheless, many approaches are not optimized, require frequent administration, are associated with systemic toxicities and only show modest efficacy as monotherapies. Nanotechnology can potentially enhance the efficacy of such immunotherapies by improving the delivery, retention and release of immunostimulatory agents and biologicals in targeted cell populations and tissues. This review presents the current status and emerging trends in such nanotechnology-based cancer immunotherapies including the role of nanoparticles as carriers of immunomodulators, nanoparticles-based cancer vaccines, and depots for sustained immunostimulation. Also highlighted are key translational challenges and opportunities in this rapidly growing field.
PardollDM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol2012; 13: 1129–32.
2.
MellmanICoukosGDranoffG. Cancer immunotherapy comes of age. Nature2011; 480: 480–9.
3.
GruppSAKalosMBarrettDAplencRPorterDLRheingoldSRTeacheyDTChewAHauckBWrightJFMilone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med2013; 368: 1509–18.
4.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012; 12: 252–64.
5.
Brower V. Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst 2015; 107:4–6.
6.
GajewskiTFSchreiberHFuYX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol2013; 14: 1014–22.
7.
SchreiberRDOldLJSmythMJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science2011; 331: 1565–70.
8.
LindauDGielenPKroesenMWesselingPAdemaGJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology2013; 138: 105–15.
9.
WeberJSYangJCAtkinsMBDisisML. Toxicities of immunotherapy for the practitioner. J Clin Oncol2015; 33: 2092–9.
10.
AlatrashGJakherHStaffordPDMittendorfEA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf2013; 12: 631–45.
11.
LakeRARobinsonBW. Immunotherapy and chemotherapy – a practical partnership. Nat Rev Cancer2005; 5: 397–405.
12.
JiangHChessL. How the immune system achieves self-nonself discrimination during adaptive immunity. Adv Immunol2009; 102: 95–133.
13.
SwannJBSmythMJ. Immune surveillance of tumors. J Clin Invest2007; 117: 1137–46.
14.
ZouW. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol2006; 6: 295–307.
15.
LinleyAJAhmadMReesRC. Tumour-associated antigens: considerations for their use in tumour immunotherapy. Int J Hematol2011; 93: 263–73.
VeselyMDKershawMHSchreiberRDSmythMJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol2011; 29: 235–71.
18.
ShengJChenWZhuHJ. The immune suppressive function of transforming growth factor-beta (TGF-beta) in human diseases. Growth Factors2015; 33: 92–101.
19.
OleinikaKNibbsRJGrahamGJFraserAR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol2013; 171: 36–45.
20.
GabrilovichDINagarajS. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol2009; 9: 162–74.
21.
ChanmeeTOntongPKonnoKItanoN. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel)2014; 6: 1670–90.
22.
RosenbergSARestifoNP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science2015; 348: 62–68.
23.
MeleroIGaudernackGGerritsenWHuberCParmianiGSchollSThatcherNWagstaffJZielinskiCFaulknerIMellstedtH. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol2014; 11: 509–24.
24.
MahoneyKMRennertPDFreemanGJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov2015; 14: 561–84.
25.
MitragotriSAndersonDGChenXChowEKHoDKabanovAVKarpJMKataokaKMirkinCAPetroskoSHShi J, Stevens MM, Sun S, Teoh S, Venkatraman SS, Xia Y, Wang S, Gu Z, Xu C. Accelerating the translation of nanomaterials in biomedicine. ACS Nano2015; 9: 6644–54.
26.
PeerDKarpJMHongSFarokhzadOCMargalitRLangerR. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol2007; 2: 751–60.
VentolaCL. The nanomedicine revolution: part 2: current and future clinical applications. P T2012; 37: 582–91.
29.
PlummerRWilsonRHCalvertHBoddyAVGriffinMSluddenJTilbyMJEatockMPearsonDGOttleyCJMatsumura Y, Kataoka K, Nishiya T. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer2011; 104: 593–8.
30.
DavisMEZuckermanJEChoiCHSeligsonDTolcherAAlabiCAYenYHeidelJDRibasA. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature2010; 464: 1067–70.
31.
CastroJEMelo-CardenasJUrquizaMBarajas-GamboaJSPakbazRSKippsTJ. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res2012; 72: 2937–48.
32.
ZuckermanJEGritliITolcherAHeidelJDLimDMorganRChmielowskiBRibasADavisMEYenY. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA2014; 111: 11449–54.
33.
SmithDMSimonJKBakerJRJr. Applications of nanotechnology for immunology. Nat Rev Immunol2013; 13: 592–605.
34.
ShengWYHuangL. Cancer immunotherapy and nanomedicine. Pharm Res2011; 28: 200–14.
35.
GoldbergMS. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell2015; 161: 201–4.
36.
NicholasCLesinskiGB. Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy2011; 3: 673–90.
37.
RosenbergSA. IL-2: the first effective immunotherapy for human cancer. J Immunol2014; 192: 5451–8.
38.
DavisMRZhuZHansenDMBaiQFangY. The role of IL-21 in immunity and cancer. Cancer Lett2015; 358: 107–114.
39.
TianHShiGYangGZhangJLiYDuTWangJXuFChengLZhangXDai L, Chen X, Zhang S, Yang Y, Yu D, Wei Y, Deng H. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer2014; 14: 48–48.
40.
ZitvogelLGalluzziLKeppOSmythMJKroemerG. Type I interferons in anticancer immunity. Nat Rev Immunol2015; 15: 405–14.
41.
TagawaMKawamuraKLiQTadaYHiroshimaKShimadaH. A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects. Clin Dev Immunol2011; 2011: 479013–479013.
42.
ShirotaHKlinmanDM. Use of CpG oligonucleotides for cancer immunotherapy and their effect on immunity in the tumor microenvironment. Immunotherapy2013; 5: 787–9.
VannemanMDranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer2012; 12: 237–51.
45.
KwongBLiuHIrvineDJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials2011; 32: 5134–47.
46.
KwongBGaiSAElkhaderJWittrupKDIrvineDJ. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res2013; 73: 1547–58.
47.
BartholdyCKauffmannSOChristensenJPThomsenAR. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol2007; 178: 1662–70.
48.
BernerVLiuHZhouQAldersonKLSunKWeissJMBackTCLongoDLBlazarBRWiltroutRHDai L, Chen X, Zhang S, Yang Y, Yu D, Wei Y, Deng H. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med2007; 13: 354–60.
49.
HeikenwalderMPolymenidouMJuntTSigurdsonCWagnerHAkiraSZinkernagelRAguzziA. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med2004; 10: 187–192.
50.
WingenderGGarbiNSchumakBJungerkesFEndlEvon BubnoffDSteitzJStrieglerJMoldenhauerGTutingTHeit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol2006; 36: 12–20.
51.
DonohueJHRosenbergSA. The fate of interleukin-2 after in vivo administration. J Immunol1983; 130: 2203–8.
52.
AtkinsMBMierJWParkinsonDRGouldJABerkmanEMKaplanMM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med1988; 318: 1557–63.
53.
KlempnerMSNoringRMierJWAtkinsMB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med1990; 322: 959–65.
54.
BoymanOSurhCDSprentJ. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther2006; 6: 1323–31.
55.
ChristianDAHunterCA. Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy2012; 4: 425–41.
56.
PetrosRADeSimoneJM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov2010; 9: 615–27.
57.
van der VeenAHEggermontAMSeynhaeveALvanTten HagenTL. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer1998; 77: 901–6.
58.
KedarEGurHBabaiISamiraSEven-ChenSBarenholzY. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother2000; 23: 131–45.
59.
KedarEPalgiOGolodGBabaiIBarenholzY. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother1997; 20: 180–193.
60.
EppsteinDAStewartWE2nd. Altered pharmacological properties of liposome-associated human interferon-alpha. J Virol1982; 41: 575–82.
61.
AndersonPMKatsanisESencerSFHaszDOchoaACBostromB. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother (1991)1992; 12: 19–31.
62.
YuyamaYTsujimotoMFujimotoYOkuN. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines. Cancer Lett2000; 155: 71–7.
63.
ten HagenTLSeynhaeveALvan TielSTRuiterDJEggermontAM. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer2002; 97: 115–120.
64.
HeffernanMJKasturiSPYangSCPulendranBMurthyN. The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials2009; 30: 910–18.
DavisMEChenZGShinDM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov2008; 7: 771–82.
67.
MaedaHNakamuraHFangJ. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev2013; 65: 71–79.
68.
XuZWangYZhangLHuangL. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano2014; 8: 3636–45.
69.
ZhaoYHuoMXuZWangYHuangL. Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma. Biomaterials2015; 68: 54–66.
70.
ParkJWrzesinskiSHSternELookMCriscioneJRaghebRJaySMDementoSLAgawuALicona LimonPFerrandino AF, Gonzalez D, Habermann A, Flavell RA, Fahmy TM. Combination delivery of TGF-beta inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater2012; 11: 895–905.
71.
Cubillos-RuizJREngleXScarlettUKMartinezDBarberAElguetaRWangLNesbethYDurantYGewirtzATSentman CL, Kedl R, Conejo-Garcia JR. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest2009; 119: 2231–44.
72.
KanaokaETakahashiKYoshikawaTJizomotoHNishiharaYUchidaNMaekawaRHiranoK. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J Control Release2002; 82: 183–7.
73.
NevilleMERobbRJPopescuMC. In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. Cytokine2001; 16: 239–50.
74.
LinAYAlmeidaJPBearALiuNLuoLFosterAEDrezekRA. Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One2013; 8: e63550–e63550.
75.
HuangZZhangZJiangYZhangDChenJDongLZhangJ. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release2012; 158: 286–92.
76.
ZhuSNiuMO'MaryHCuiZ. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm2013; 10: 3525–30.
77.
SmithBRGhosnEERallapalliHPrescherJALarsonTHerzenbergLAGambhirSS. Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat Nanotechnol2014; 9: 481–7.
78.
CondeJBaoCCTanYQCuiDXEdelmanERAzevedoHSByrneHJArtziNTianFR. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells. Adv Funct Mater2015; 25: 4183–94.
79.
ChampionJAMitragotriS. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res2009; 26: 244–9.
80.
KumarSAnselmoACBanerjeeAZakrewskyMMitragotriS. Shape and size-dependent immune response to antigen-carrying nanoparticles. J Control Release2015; 220(Pt A): 141–8.
81.
PericaKTuARichterABielerJGEdidinMSchneckJP. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano2014; 8: 2252–60.
ZhengYStephanMTGaiSAAbrahamWShearerAIrvineDJ. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release2013; 172: 426–35.
84.
Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, Fiering S. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol 2015.
85.
IrvineDJHansonMCRakhraKTokatlianT. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev2015; 115: 11109–46.
86.
BolhassaniASafaiyanSRafatiS. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer2011; 10: 3–3.
87.
AzvolinskyA. Cancer vaccines: always a bridesmaid, never a bride?J Natl Cancer Inst2013; 105: 248–9.
88.
KrishnamachariYGearySMLemkeCDSalemAK. Nanoparticle delivery systems in cancer vaccines. Pharm Res2011; 28: 215–36.
89.
CohenEPChopraAIOSKimTS. Enhancing cellular cancer vaccines. Immunotherapy2009; 1: 495–504.
90.
RosenbergSAYangJCRestifoNP. Cancer immunotherapy: moving beyond current vaccines. Nature Med2004; 10: 909–15.
91.
AltinJGParishCR. Liposomal vaccines – targeting the delivery of antigen. Methods2006; 40: 39–52.
92.
DubenskyTWJr.ReedSG. Adjuvants for cancer vaccines. Semin Immunol2010; 22: 155–61.
93.
LimaKMdos SantosSARodriguesJMJr.SilvaCL. Vaccine adjuvant: it makes the difference. Vaccine2004; 22: 2374–79.
94.
WinterHFoxBARuttingerD. Future of cancer vaccines. Methods Mol Biol2014; 1139: 555–64.
95.
FanYMoonJJ. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines (Basel)2015; 3: 662–85.
96.
ShaoKSinghaSClemente-CasaresXTsaiSYangYSantamariaP. Nanoparticle-based immunotherapy for cancer. ACS Nano2015; 9: 16–30.
IrvineDJSwartzMASzetoGL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater2013; 12: 978–90.
99.
GallucciSMatzingerP. Danger signals: SOS to the immune system. Curr Opin Immunol2001; 13: 114–19.
100.
MatzingerP. Tolerance, danger, and the extended family. Annu Rev Immunol1994; 12: 991–1045.
101.
BachmannMFRohrerUHKundigTMBurkiKHengartnerHZinkernagelRM. The influence of antigen organization on B cell responsiveness. Science1993; 262: 1448–51.
102.
PasareCMedzhitovR. Control of B-cell responses by toll-like receptors. Nature2005; 438: 364–8.
103.
ShuklaSWenAMCommandeurUSteinmetzNF. Presentation of HER2 epitopes using a filamentous plant virus-based vaccination platform. J Mater Chem B2014; 2: 6249–58.
104.
JobsriJAllenARajagopalDShiptonMKanyukaKLomonossoffGPOttensmeierCDieboldSSStevensonFKSavelyevaN. Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody. PLoS One2015; 10: e0118096–e0118096.
105.
ScheerlinckJPGreenwoodDL. Virus-sized vaccine delivery systems. Drug Discov Today2008; 13: 882–7.
106.
RiedelTGhasparianAMoehleKRusertPTrkolaARobinsonJA. Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. Chembiochem2011; 12: 2829–36.
107.
Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010.
108.
NoadRRoyP. Virus-like particles as immunogens. Trends Microbiol2003; 11: 438–44.
109.
FangRHKrollAVZhangL. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy. Small2015; 11: 5483–96.
110.
JoffreOPSeguraESavinaAAmigorenaS. Cross-presentation by dendritic cells. Nat Rev Immunol2012; 12: 557–69.
111.
MolinoNMAndersonAKNelsonELWangSW. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano2013; 7: 9743–52.
112.
SalujaSSHanlonDJSharpFAHongEKhalilDRobinsonETigelaarRFahmyTMEdelsonRL. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen. Int J Nanomedicine2014; 9: 5231–46.
113.
SharpFARuaneDClaassBCreaghEHarrisJMalyalaPSinghMO'HaganDTPetrilliVTschoppJO'Neill LA, Lavelle EC. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A2009; 106: 870–5.
114.
LiPLuoZLiuPGaoNZhangYPanHLiuLWangCCaiLMaY. Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses. J Control Release2013; 168: 271–9.
115.
HuYLitwinTNagarajaARKwongBKatzJWatsonNIrvineDJ. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett2007; 7: 3056–64.
116.
MukaiYYoshinagaTYoshikawaMMatsuoKYoshikawaTMatsuoKNikiKYoshiokaYOkadaNNakagawaS. Induction of endoplasmic reticulum-endosome fusion for antigen cross-presentation induced by poly (gamma-glutamic acid) nanoparticles. J Immunol2011; 187: 6249–55.
117.
ReddySTvan der VliesAJSimeoniEAngeliVRandolphGJO'NeilCPLeeLKSwartzMAHubbellJA. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol2007; 25: 1159–64.
118.
ThomasSNVokaliELundAWHubbellJASwartzMA. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials2014; 35: 814–24.
119.
RosaliaRACruzLJvan DuikerenSTrompATSilvaALJiskootWde GruijlTLowikCOostendorpJvan der BurgSHOssendorp F. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials2015; 40: 88–97.
120.
HardyCLLemasurierJSMohamudRYaoJXiangSDRollandJMO'HehirREPlebanskiM. Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. J Immunol2013; 191: 5278–90.
121.
CruzLJTackenPJRuedaFDomingoJCAlbericioFFigdorCG. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol2012; 509: 143–63.
122.
KrupOCKrollIBoseGFalkenbergFW. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother1999; 22: 525–38.
123.
NeelapuSSGauseBLHarveyLLeeSTFryeARHortonJRobbRJPopescuMCKwakLW. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood2007; 109: 5160–3.
124.
HanesJSillsAZhaoZSuhKWTylerBDiMecoFBratDJChotiMALeongKWPardollDMBremH. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res2001; 18: 899–906.
125.
SabelMSHillHJongYSMathiowitzEBankertRBEgilmezNK. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery2001; 130: 470–8.
126.
HillHCConwayTFJr.SabelMSJongYSMathiowitzEBankertRBEgilmezNK. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res2002; 62: 7254–63.
127.
KarkadaMBerinsteinNLMansourM. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics2014; 8: 27–38.
128.
EggermontLJPaulisLETelJFigdorCG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol2014; 32: 456–65.
129.
van der WeijdenJPaulisLEVerdoesMvan HestJCMFigdorCG. The right touch: design of artificial antigen-presenting cells to stimulate the immune system. Chem Sci2014; 5: 3355–67.
130.
SunshineJCPericaKSchneckJPGreenJJ. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials2014; 35: 269–77.
131.
ZhangSX. Turning killer into cure – the story of oncolytic herpes simplex viruses. Discov Med2015; 20: 303–9.
132.
LiuTLiLFuCLiuHChenDTangF. Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. Biomaterials2012; 33: 2399–407.
133.
ChenQXueYSunJ. Kupffer cell-mediated hepatic injury induced by silica nanoparticles in vitro and in vivo. Int J Nanomed2013; 8: 1129–40.
134.
MoonCParkHJChoiYHParkEMCastranovaVKangJL. Pulmonary inflammation after intraperitoneal administration of ultrafine titanium dioxide (TiO2) at rest or in lungs primed with lipopolysaccharide. J Toxicol Environ Health A2010; 73: 396–409.
135.
ShvedovaAAKisinERMercerRMurrayARJohnsonVJPotapovichAITyurinaYYGorelikOArepalliSSchwegler-BerryDHubbs AF, Antonini J, Evans DE, Ku BK, Ramsey D, Maynard A, Kagan VE, Castranova V, Baron P. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol2005; 289: L698–708.
136.
AggarwalPHallJBMcLelandCBDobrovolskaiaMAMcNeilSE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev2009; 61: 428–37.
137.
ParkK. Facing the truth about nanotechnology in drug delivery. ACS Nano2013; 7: 7442–7.
138.
BlancoEShenHFerrariM. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol2015; 33: 941–51.
139.
NelAEMadlerLVelegolDXiaTHoekEMSomasundaranPKlaessigFCastranovaVThompsonM. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater2009; 8: 543–57.
140.
PillaLRivoltiniLPatuzzoRMarrariAValdagniRParmianiG. Multipeptide vaccination in cancer patients. Expert Opin Biol Ther2009; 9: 1043–55.
141.
MortonSWHerlihyKPShopsowitzKEDengZJChuKSBowermanCJDesimoneJMHammondPT. Scalable manufacture of built-to-order nanomedicine: spray-assisted layer-by-layer functionalization of PRINT nanoparticles. Adv Mater2013; 25: 4707–13.
142.
SteinmetzNF. Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine2010; 6: 634–41.
143.
PokorskiJKSteinmetzNF. The art of engineering viral nanoparticles. Mol Pharm2011; 8: 29–43.
144.
DePorterSMMcNaughtonBR. Engineered M13 bacteriophage nanocarriers for intracellular delivery of exogenous proteins to human prostate cancer cells. Bioconjug Chem2014; 25: 1620–25.
145.
ShuklaSEberFJNagarajanASDiFrancoNASchmidtNWenAMEibenSTwymanRMWegeCSteinmetzNF. The impact of aspect ratio on the biodistribution and tumor homing of rigid soft-matter nanorods. Adv Healthcare Mater2015; 4: 874–82.
146.
ChengFTsvetkovaIBKhuongYLMooreAWArnoldRJGoicocheaNLDragneaBMukhopadhyayS. The packaging of different cargo into enveloped viral nanoparticles. Mol Pharm2013; 10: 51–58.
147.
Lee KL, Twyman RM, Fiering S, Steinmetz NF. Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016; Epub ahead of print 19 January. DOI: 10.1002/wnan.1383.
